Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06747273 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States
A Phase 1 study, sponsored by Sarepta Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT06747273 is a Phase 1 study that was terminated before completion, run by Sarepta Therapeutics. The registered enrollment target is 4 participants.
The verdict
NCT06747273, a Phase 1 study, was terminated before completion, sponsored by Sarepta Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety of SRP-9004.
Interventions
- DRUG SRP-9004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2025-01-09 |
| Est. Completion | 2025-06-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06747273
The ClinicalTrials.gov registry entry for NCT06747273 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarepta Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SRP-9004 is the first listed.
NCT06747273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06747273 about?
NCT06747273 is a clinical study titled "Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States". The primary objective of this study is to evaluate the safety of SRP-9004.
What is the current status of trial NCT06747273?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2025-01-09. Estimated completion is 2025-06-18.
What interventions are being tested in trial NCT06747273?
The interventions under investigation include: SRP-9004 (DRUG).
Who is sponsoring clinical trial NCT06747273?
This trial is sponsored by Sarepta Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.